Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Skye Bioscience (Nasdaq:SKYE) Reports Phase 1b Nimacimab Results in MASLD Patients

Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …

Team Kalkine | 19 September 2025

CytomX Therapeutics (NASDAQ: CTMX) Stock Rating Upgraded by Barclays

CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.

Aditi Sarkar | 19 September 2025

Lam Research (NASDAQ:LRCX) Q4 FY2025 Results: Revenue Growth and Margins Improve

Lam Research Corporation (NASDAQ:LRCX) reported results for the quarter ended June 29, 2025, showing sequential and year-on-year growth across revenue, earnings, and margins. Quarterly revenue reachedUS$5.171 billion, representing a 9.6% increase from the March quarter and a 33.6% rise compared to the same period …

Team Kalkine | 18 September 2025

Baker Hughes (NASDAQ:BKR) Target Price Raised as Analysts Update Ratings

Baker Hughes (NASDAQ:BKR) had its price target increased by Capital One Financial, which lifted its objective from USD 49.00 to USD 53.00 in a report issued Tuesday. The firm maintained an “overweight” rating, with the new price objective implying a potential upside of 12.13% …

Aditi Sarkar | 17 September 2025

Biogen (Nasdaq: BIIB) Gains EU Approval for ZURZUVAE in Post-Partum Depression

Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) for the treatment of post-partum depression (PPD) in adults following childbirth. The decision makes ZURZUVAE the first and only treatment specifically indicated for PPD in the European …

Team Kalkine | 17 September 2025

Federal Reserve Cuts Rates Amidst Economic Uncertainty: A Look at the Market Outlook

In a move that was largely anticipated by Wall Street, the U.S. Federal Reserve's Federal Open Market Committee (FOMC) announced a quarter-percentage-point cut to the federal funds rate on September 17, 2025. This brings the new target range to 4% to 4.25%. The decision …

Team Kalkine | 17 September 2025

Lloyds Banking Group Expands Multi-Year IT Partnership with Broadcom (NASDAQ: AVGO, LSE: LLOY)

Lloyds Banking Group and Broadcom Inc. (NASDAQ: AVGO) have announced an expansion of their multi-year technology partnership, focusing on infrastructure software and cloud solutions to support the bank’s ongoing digital transformation. The agreement extends the Group’s access to Broadcom’s software portfolio, including VMware Cloud …

Team Kalkine | 17 September 2025

Nasdaq Leaders Shine: Semiconductors and Energy Stocks Drive NASDAQ Movers on Fed Hopes

On September 16, 2025, the Nasdaq Composite and S&P 500 registered record intraday highs but ended the day slightly lower, with the Nasdaq closing down about0.1%. Markets were largely driven by growing anticipation of aFederal Reserve interest rate cutand stronger-than-expected August retail sales, which …

Team Kalkine | 16 September 2025